Tan Wenhui, Xiao Changkai, Ma Min, Cao Youhan, Huang Zhenguo, Wang Xiaolan, Kang Ran, Li Zhenfa, Li Ermao
Institute of Translational Medicine, Hengyang Medical College, University of South China, Hengyang, 421001, Hunan, China.
Department of Urology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Cancer Gene Ther. 2025 Jan;32(1):1-10. doi: 10.1038/s41417-024-00834-z. Epub 2024 Nov 4.
The treatment of prostate cancer (PCa) has made great progress in recent years, but treatment resistance always develops and can even lead to fatal disease. Exploring the mechanism of drug resistance is of great significance for improving treatment outcomes and developing biomarkers with predictive value. It is increasingly recognized that mechanism of drug resistance in advanced PCa is related to lineage plasticity and tissue differentiation. Specifically, one of the mechanisms by which castration-resistant prostate cancer (CRPC) cells acquire drug resistance and transform into neuroendocrine prostate cancer (NEPC) cells is lineage plasticity. NEPC is a subtype of PCa that is highly aggressive and lethal, with a median survival of only 7 months. With the development of high-throughput RNA sequencing technology, more and more non-coding RNAs have been identified, which play important roles in different diseases through different mechanisms. Several ncRNAs have shown great potential in PCa lineage plasticity and as biomarkers. In the review, the role of ncRNA in PCa lineage plasticity and its use as biomarkers were reviewed.
近年来，前列腺癌（PCa）的治疗取得了很大进展，但治疗耐药性总是会出现，甚至可能导致疾病致命。探索耐药机制对于改善治疗效果和开发具有预测价值的生物标志物具有重要意义。人们越来越认识到，晚期PCa的耐药机制与谱系可塑性和组织分化有关。具体而言，去势抵抗性前列腺癌（CRPC）细胞获得耐药性并转化为神经内分泌前列腺癌（NEPC）细胞的机制之一是谱系可塑性。NEPC是PCa的一种亚型，具有高度侵袭性和致死性，中位生存期仅为7个月。随着高通量RNA测序技术的发展，越来越多的非编码RNA被鉴定出来，它们通过不同机制在不同疾病中发挥重要作用。几种非编码RNA在PCa谱系可塑性和作为生物标志物方面显示出巨大潜力。在这篇综述中，对非编码RNA在PCa谱系可塑性中的作用及其作为生物标志物的应用进行了综述。
